Source	E. coli-derived human PSAT1 protein Met1-Leu370 with a C-terminal 6-His tag
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin level	<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal sequence Analysis	Met1
Predicted Molecular Mass	41 kDa
SDS-PAGE	40 kDa, under reducing conditions
Activity	Measured by its ability to produce 3-phosphooxypyruvate. The specific activity is >130 pmol/min/μg, as measured under the described conditions.

Recombinant Human PSAT1 His-tag Protein, CF Scientific Data Examples

	Recombinant Human PSAT1 His-tag Protein Enzyme Activity Recombinant Human PSAT1 His-tag (Catalog # 10342-PS) is measured by its ability to produce 3-phosphooxypyruvate.
	Recombinant Human PSAT1 His-tag Protein SDS-PAGE 2 μg/lane of Recombinant Human PSAT1 His-tag (Catalog # 10342-PS) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing a band at 40 kDa under reducing conditions.

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10342-PS

Formulation	Supplied as a 0.2 μm filtered solution in MES and NaCl.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after opening.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: PSAT1

Phosphoserine aminotransferase (PSAT1), a pyridoxal-phosphate (PLP)-dependent cytosolic protein catalyzes the conversion of 3-phosphohydroxypyruvate into phosphoserine; the reversible second step in the de novo serine synthesis pathway. PSAT1 forms an active a/b domain structure homodimer where each monomer is 40 kDa and 370 amino acids (1). PSAT1 contains a catalytic lysine and bound PLP in the active site. Although serine is considered a nonessential amino acid, de novo synthesis is essential in the brain due to insufficient delivery through the blood brain barrier. PSAT1 expression is concentrated in brain, liver, kidney, and pancreas suggesting these tissues are primary sites for de novo serine synthesis (2). Mutations in PSAT1 can cause Neu-Laxova syndrome, a serine-deficiency disorder (3). PSAT1 has been reported to signal through the GSK3beta/beta-catenin pathway (4, 5), regulate alpha keto-glutarate in a role essential for embryonic stem cell self-renewal and pluripotency (6) and promote migratory metastasis and proliferation in roles independent of serine synthesis (7,8). PSAT1 is up-regulated and associated with poor prognosis in several cancers including nasopharyngeal (9), breast (10), and esophageal squamous carcinoma (11). PSAT1 has been proposed as a promising target for tumor suppression in colorectal, esophageal, and breast cancers (8, 12, 13). It has been proposed as a target in brain tumors through a novel stabilization mechanism (14) and for inhibition of the serine production pathway in tuberculosis (15).

Item	Value
References	Singh, R. S. et al. (2019) Int. J. Biol. Macromol. 132:1012. Baek, J. Y. et al. (2003) Biochem. J. 373:191. Acuna-Hidalgo, R. et al. (2014) Am. J. Hum. Genet. 95:285. Gao, S. et al. (2017) J. Exp. Clin. Cancer Res. 36:179. Dai, J. et al. (2019) J. Transl. Med. 17:190. Hwang, I. Y. et al. (2016) Cell Metab. 24:494. Yang, Y. et al. (2015) Int. J. Cancer 136:E39. Metcalf, S. et al. (2019) Clin. Exp. Metastasis. [epub ahead of print] Liao, K. M. et al. (2016) J. Cancer 7:1088. De Marchi, T. et al. (2017) Sci. Rep. 7:2099. Liu, B. et al. (2016) Cell Physiol. Biochem. 39:395. Yang, Y. et al. (2018) Cancer Manag. Res. 10:6537. Sun, C. et al. (2018) Cancer Manag. Res. 10:4581. Jiang, J. et al. (2019) Autophagy. [epub ahead of print] Haufroid, M. and Wouters, J. (2019) Pharmaceuticals 12:E66.
Long Name	Phosphoserine Aminotransferase 1
Entrez Gene IDs	29968 (Human); 107272 (Mouse)
Alternate Names	EC 2.6.1.52, EPIP, PSAMGC1460, PSAT, PSAT1, PSATD, PSATendometrial progesterone-induced protein, Phosphohydroxythreonine aminotransferase, phosphoserine aminotransferase, phosphoserine aminotransferase 1

Citations for Recombinant Human PSAT1 His-tag Protein, CF

View all citations for the Proteins and Enzymes platform.
Please visit our Instrument Citation Database to search our collection of scientific articles that feature our instruments.

Recombinant Human PSAT1 His-tag Protein, CF

Order Information

Shipping Information

Key Product Details

Complete Your Research

Product Specifications